9 Biotechnology Stocks to Buy Now

9 Biotechnology Stocks to Buy Now

This week, 9 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Anacor Pharmaceuticals, Inc. (ANAC) is seeing ratings go up from a C last week to a B this week. Anacor Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ANAC stock.

The rating of Seattle Genetics, Inc. (SGEN) moves up this week, rising from a C to a B. Seattle Genetics, Inc. is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Coherus BioSciences, Inc.’s (CHRS) ratings are looking better this week, moving up to a B from last week’s C. Coherus BioSciences, Inc. focuses on developing and commercializing biosimilar products worldwide. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

Concert Pharmaceuticals, Inc. (CNCE) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

Ignyta, Inc. (RXDX) boosts its rating from a C to a B this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of RXDX stock.

Anthera Pharmaceuticals, Inc. (ANTH) gets a higher grade this week, advancing from a C last week to a B. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of ANTH stock.

Fortress Biotech, Inc. (FBIO) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of FBIO stock.

Synergy Pharmaceuticals, Inc. (SGYP) improves from a C to a B rating this week. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

This week, Vascular Biogenics Ltd.’s (VBLT) ratings are up from a C last week to a B. The company also gets A’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VBLT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/9-biotechnology-stocks-to-buy-now-2/.

©2019 InvestorPlace Media, LLC